This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Review paper

Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer

Volume: 30, Issue: 4, Pages: 343 - 350
Published: Mar 1, 2021
Abstract
Introduction: The prognosis of patients with advanced biliary tract cancer (BTC) remains dismal, with a 5-year overall survival rate of less than 10%. Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of several hematological and solid tumors, controversial results have been reported in BTC. In this setting, the anti-PD-L1 inhibitor durvalumab is currently under investigation in several clinical trials as...
Paper Details
Title
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Published Date
Mar 1, 2021
Volume
30
Issue
4
Pages
343 - 350
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.